A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Clinical trial NCT03755518 · TERMINATED

Trial details

NCT number: NCT03755518
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Myelofibrosis Post-essential Thrombocythemia Myelofibrosis

Start date: 2019-03-27
Primary completion: 2021-11-26
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.